Michelle Carr, Author at BioTuesdays

Developments

Ripple and Glaukos ink evaluation and licensing agreements

Closely-held Ripple Therapeutics has announced evaluation and licensing agreements with Glaukos Corporation (NYSE:GKOS), enabling Glaukos to leverage Ripple’s proprietary technology platform to create sustained release...

October 15, 2024

Developments

Aurinia presents new real-world data reinforcing LUPKYNIS in LN at ASN Kidney Week 2024

Aurinia Pharmaceuticals (NASDAQ:AUPH) has announced plans to present new data reinforcing the clinical significance of LUPKYNIS in the treatment of lupus nephritis (LN) at the American Society of Nephrology (ASN) Kidney...

October 11, 2024

Executive Moves

MaxCyte appoints Ali Soleymannezhad as CCO

MaxCyte (NASDAQ:MXCT; LSE:MXCT) has appointed Ali Soleymannezhad as chief commercial officer, effective September 11, 2024. Prior to this role, Mr. Soleymannezhad served as executive vice president of bioprocessing at...

October 10, 2024

Developments

Clearmind receives IRB approval for trial of CMND-100 for AUD at second clinical site

Clearmind Medicine (NASDAQ:CMND) has announced that it has received Institutional Review Board (IRB) approval from one of its U.S. clinical sites for part A of its Phase I/IIa clinical trial of CMND-100 for the...

October 10, 2024

Uncategorized

test

audio test

September 26, 2024

Markets

BTIG starts Definitive Healthcare at buy; PT $7

BTIG launched coverage of Definitive Healthcare (NASDAQ:DH) with a “buy” rating and $7 target price. The stock closed at $4.44 on September 16. Definitive Healthcare is one of the industry’s most comprehensive...

September 18, 2024

Developments

Inspira secures additional U.S. patent approval for blood oxygenation system

Inspira Technologies (NASDAQ:IINN) has announced the approval of a second U.S. patent for VORTEX, its orbiting blood oxygenation delivery system designed to oxygenate blood without the use of fibre membranes, bringing...

September 16, 2024

Developments

Aurinia reports first participant dosed milestone for potential therapy in autoimmune diseases

Aurinia Pharmaceuticals (NASDAQ:AUPH) has announced that the first participant has been dosed in its Phase 1a study of AUR200, a differentiated, best-in-class potential therapy for autoimmune diseases targeting B-cell...

September 5, 2024

Markets

Exicure announces reverse split to gain Nasdaq compliance

Exicure (NASDAQ:XCUR) has announced a 1-for-5 reverse stock split of its outstanding common shares. The reverse stock split is expected to become effective at 5:00 p.m. on August 27, 2024, with the common stock...

August 26, 2024

Developments

Perimeter reports progress on several fronts

Perimeter Medical Imaging AI (TSX:PINK; OTC:PYNKF; FSE:4PC) highlighted several positive developments and achievements in its Q2 report and conference call yesterday. Perimeter is a medical technology company working to...

August 15, 2024

Author - Michelle Carr

Ripple and Glaukos ink evaluation and licensing agreements

Aurinia presents new real-world data reinforcing LUPKYNIS in LN at ASN Kidney Week 2024

MaxCyte appoints Ali Soleymannezhad as CCO

Clearmind receives IRB approval for trial of CMND-100 for AUD at second clinical site

test

BTIG starts Definitive Healthcare at buy; PT $7

Inspira secures additional U.S. patent approval for blood oxygenation system

Aurinia reports first participant dosed milestone for potential therapy in autoimmune diseases

Exicure announces reverse split to gain Nasdaq compliance

Perimeter reports progress on several fronts

Subscribe